Journal of Cardiovascular Pharmacology最新文献_第3页

Procyanidin B2 attenuates pathological cardiac fibrosis and inflammation: role of PPARγ.

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-02-19 DOI: 10.1097/FJC.0000000000001684

Chun Xia Li, Ruo Man Wu, Qian Lin Xie, Fei Wang, Xiao Le Xu

{"title":"Procyanidin B2 attenuates pathological cardiac fibrosis and inflammation: role of PPARγ.","authors":"Chun Xia Li, Ruo Man Wu, Qian Lin Xie, Fei Wang, Xiao Le Xu","doi":"10.1097/FJC.0000000000001684","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001684","url":null,"abstract":"Procyanidin B2 (PB2) is a prominent procyanidin isomer. Its effects and mechanisms in cardiac remodeling are not fully understood. Peroxisome proliferator-activated receptor gamma (PPAR-γ) plays a crucial role in regulating cardiac hypertrophy, fibrosis, and inflammation. This study aims to investigate the effect of PB2 on pathological cardiac fibrosis and inflammation, focusing on the underlying mechanisms involving PPAR-γ. In vitro, cardiac fibrosis was induced in cardiac fibroblasts using angiotensin II. In vivo, a mouse model of pathological cardiac fibrosis was generated through transverse aortic constriction to induce pressure overload. We found that PB2 inhibited proliferation, differentiation, collagen accumulation, and the NF-κB inflammation pathway in cardiac fibroblasts triggered by angiotensin II. These inhibitory effects were negated by the PPAR-γ antagonist GW9662 and RNA interference. Additionally, PB2 directly elevated PPAR-γ expression in cardiac fibroblasts. Similarly, PB2 alleviated transverse aortic constriction-induced cardiac dysfunction, myocardial fibrosis, and inflammation in mice. These cardioprotective effects of PB2 in vivo were counteracted by co-administration with GW9662. Correspondingly, the upregulation of PPAR-γ protein expression by PB2 in pressure-overloaded hearts was also counteracted by GW9662 co-administration. In conclusion, this study demonstrates that PB2 exerts protective effects against pathological cardiac fibrosis and inflammation through a PPAR-γ dependent mechanism.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Deciphering the Role of In-hospital Bleeding in Acute Coronary Syndromes.

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-02-17 DOI: 10.1097/FJC.0000000000001685

Felice Gragnano, Paolo Calabrò, Dominick J Angiolillo

引用次数: 0

Decastatin, a novel Non-Collagenous 1 domain from collagen type X, harbors a specific fragment with antiangiogenic properties.

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-02-11 DOI: 10.1097/FJC.0000000000001683

Stine Marie Jansen, Rastislav Pitek, Morten Asser Karsdal, Kim Henriksen

{"title":"Decastatin, a novel Non-Collagenous 1 domain from collagen type X, harbors a specific fragment with antiangiogenic properties.","authors":"Stine Marie Jansen, Rastislav Pitek, Morten Asser Karsdal, Kim Henriksen","doi":"10.1097/FJC.0000000000001683","DOIUrl":"10.1097/FJC.0000000000001683","url":null,"abstract":"The NC1 domains of collagens have been shown to possess antiangiogenic potential and, therefore, are of therapeutic interest for cancer. However, endostatin and other NC1 domains have not been successful in clinical tests. Therefore, we used evolutionary conservation to perform molecular deconstruction of the domains to further understand their structure-activity relationship, thereby deciphering their antiangiogenic potential. Homology exploration revealed that collagen type X contains a highly interesting NC1 domain (decastatin), with several sequences showing significant homology with vastatin, which is a known collagen type VIII-derived NC1 domain. For comparison, endostatin and vastatin were split into fragments, some of which contained highly conserved regions. The testing of these peptides revealed that the peptides containing conserved regions induced signaling, and fragment four of decastatin showed the highest potency of all fragments, with a calculated IC 50 value of 2.7 μM in the human umbilical vein endothelial cell (HUVEC)-based tube formation assay, which is like that of an intact NC1 domain. Notably, the corresponding fragment from vastatin (V4) also inhibited tube formation, suggesting that this region is of therapeutic interest. In summary, we used evolutionary conservation to identify a novel NC1 domain of collagen type X, a collagen playing a role in angiogenesis of the growth plate. Furthermore, we provided data indicating that the antiangiogenic activity of NC1 domain-derived peptides reside within their conserved domains. As a result, we identified a fragment called Decastatin fragment 4 (D4) derived from the NC1 domain of collagen type X, and which has potent antiangiogenic activity.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of Indobufen in coronary artery disease: the story of a neglected drug. A systematic review.

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-02-11 DOI: 10.1097/FJC.0000000000001681

Martino Pepe, Rocco Tritto, Gianluigi Napoli, Salvatore Giordano, Roberta Romito, Giuseppe Biondi-Zoccai, Nicola Corcione, Plinio Cirillo, Marco Matteo Ciccone

引用次数: 0

Impact of In-Hospital Bleeding on Post-Discharge Therapies and Prognosis in Acute Coronary Syndromes.

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-02-10 DOI: 10.1097/FJC.0000000000001678

Luigi Spadafora, Matteo Betti, Fabrizio D'Ascenzo, Gaetano De Ferrari, Ovidio De Filippo, Carlo Gaudio, Carlos Collet, Pierre Sabouret, Pierfrancesco Agostoni, Carlo Zivelonghi, Bianca Pernice, Gianmarco Sarto, Beatrice Simeone, Erica Rocco, Federico Russo, Salvatore Giordano, Nicola Pierucci, Alberto Testa, Stefano Cacciatore, Giuseppe Biondi-Zoccai, Marco Bernardi

{"title":"Impact of In-Hospital Bleeding on Post-Discharge Therapies and Prognosis in Acute Coronary Syndromes.","authors":"Luigi Spadafora, Matteo Betti, Fabrizio D'Ascenzo, Gaetano De Ferrari, Ovidio De Filippo, Carlo Gaudio, Carlos Collet, Pierre Sabouret, Pierfrancesco Agostoni, Carlo Zivelonghi, Bianca Pernice, Gianmarco Sarto, Beatrice Simeone, Erica Rocco, Federico Russo, Salvatore Giordano, Nicola Pierucci, Alberto Testa, Stefano Cacciatore, Giuseppe Biondi-Zoccai, Marco Bernardi","doi":"10.1097/FJC.0000000000001678","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001678","url":null,"abstract":"Acute coronary syndromes (ACS) continue to pose significant challenges for clinical practitioners, particularly regarding the prediction of mid- to long-term outcomes. This study aims to investigate the impact of in-hospital bleeding (IHB) at one-year follow-up in patients admitted for ACS. Data from 23,270 patients enrolled in the international PRAISE registry and discharged after ACS were analyzed. A total of 1,060 patients experienced IHB, while 18,765 did not; 3,445 were excluded due to missing data. The primary endpoint was all-cause mortality at 1 year. Secondary endpoints included major bleeding, reinfarction, and composite endpoints at 1 year. Patients with IHB were older, more frequently female, and had a higher prevalence of cardiovascular risk factors (all p < 0.05). At discharge, IHB patients were less likely to receive optimal medical therapy. At the one-year follow-up, all-cause mortality, major bleeding, and reinfarction were significantly higher in the IHB group (all p < 0.001). Bivariate analysis showed a strong association between IHB and all the outcomes of interest (all OR > 1; all p < 0.001). These associations remained significant even after adjusting for several covariates, except for reinfarction (OR 1.3; 95% CI 0.9-2.11; p = 0.149). Age, female sex, hypertension, and peripheral artery disease were found to be independent predictors of IHB, while DES implantation, radial access and left ventricular ejection fraction were identified as protective factors. IHB is a hallmark of frailty in ACS patients; therefore, greater attention should be given during follow-up to patients experiencing this condition.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SGLT2 Inhibitors in the Elderly: Redefining Cardiac Care Beyond Age.

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-02-10 DOI: 10.1097/FJC.0000000000001680

Marco Giuseppe Del Buono, Simone Filomia, Gianluigi Saponara, Tommaso Sanna

引用次数: 0

Relationship between ALDH2 Gene Polymorphism and Vasodilative Effect of Nitroglycerin on Coronary Arteries.

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-02-10 DOI: 10.1097/FJC.0000000000001682

Kai Zhang, Chi He, Yaliang Tong, Yuquan He

{"title":"Relationship between ALDH2 Gene Polymorphism and Vasodilative Effect of Nitroglycerin on Coronary Arteries.","authors":"Kai Zhang, Chi He, Yaliang Tong, Yuquan He","doi":"10.1097/FJC.0000000000001682","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001682","url":null,"abstract":"Aldehyde dehydrogenase 2 (ALDH2) is a key enzyme that facilitates the biological metabolism of nitroglycerin. However, no study investigated the association between ALDH2 gene polymorphism and the vasodilation of coronary arteries following intracoronary administration of nitroglycerin. In the present study, we enrolled 427 patients with suspected angina pectoris. ALDH2 genotyping was performed and all patients were given 200 µg nitroglycerin in the right coronary artery during the coronary angiography. The invasive hemodynamic parameters including systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) were monitored. The reference diameter and stenosis diameter of the right coronary artery were measured with the Stenosis Analysis 1.6 software. Both wild-type and mutant-type groups exhibited significant decreases in SBP, DBP values and increases in HR value after administration of nitroglycerin (P < 0.05). The wild-type group showed significantly higher absolute difference values in SBP when compared to the mutant-type group (P < 0.05). The mutant-type group exhibited significantly lower difference values and rates of change in reference diameter compared to the wild-type group (0.3±0.3 vs. 0.5±0.2, P < 0.001 for the difference value of diameter; 9.6±9.5 vs. 15.8±8.5, P < 0.001 for the rate of change (%)). Conversely, no differences were observed between the wild-type and mutant-type groups in terms of the difference value and rate of change of the stenosis diameter (P > 0.05). In conclusion, ALDH2 gene polymorphism (Glu504Lys) is associated with changes in invasive hemodynamic parameters and coronary artery diameter after intracoronary injection of nitroglycerin.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mineralocorticoid receptor antagonists in end-stage renal disease under renal replacement therapies: bridging the gap between cardiovascular and systemic benefit, from heart failure to myocardial infarction.

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-02-06 DOI: 10.1097/FJC.0000000000001677

Giuseppe Galati, Olga Germanova

引用次数: 0

A Game Changer for Resistant Hypertension: The Rise of Aprocitentan.

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-02-04 DOI: 10.1097/FJC.0000000000001679

Ali H Eid

{"title":"A Game Changer for Resistant Hypertension: The Rise of Aprocitentan.","authors":"Ali H Eid","doi":"10.1097/FJC.0000000000001679","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001679","url":null,"abstract":"Hypertension is a major risk factor for cardiovascular disease (CVD), and a major contributor to global morbidity and mortality. In particular, resistant hypertension (rHTN), defined as blood pressure that remains elevated despite treatment with at least three antihypertensive agents including a diuretic, continues to be a major pharmacotherapeutic challenge. Traditional antihypertensive drugs often fail in patients with rHTN, underscoring the need for novel therapies. This is a brief mini-review of aprocitentan, a new drug that promises a glimmer of hope for rHTN patients. This drug is a dual endothelin (ET) receptor antagonist that blocks both ETA and ETB receptors. Given that these two receptors are critical players in vasotone regulation, antagonizing them, such as by aprocitentan, would be expected to significantly reduce blood pressure in patients with rHTN. Indeed, the PRECISION clinical trial demonstrated aprocitentan's superior effectiveness in reducing blood pressure in resistant patients, and the effects were sustained. Aprocitentan has been recently FDA-approved, marking a major milestone in hypertension management, offering hope for patients with difficult-to-treat hypertension.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Latest evidence and perspectives of Panax notoginseng extracts and preparations for the treatment of cardiovascular diseases: a review.

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-02-04 DOI: 10.1097/FJC.0000000000001670

Chenyu Zhao, Jiamei Fu, Yingyu Wang, Yabin Zhou

{"title":"Latest evidence and perspectives of Panax notoginseng extracts and preparations for the treatment of cardiovascular diseases: a review.","authors":"Chenyu Zhao, Jiamei Fu, Yingyu Wang, Yabin Zhou","doi":"10.1097/FJC.0000000000001670","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001670","url":null,"abstract":"Cardiovascular diseases are a major cause of death worldwide, and their high incidence poses a significant threat to human health and public health systems. Panax notoginseng, a traditional Chinese medicinal herb with a long history, has shown promise in treating cardiovascular diseases. This review examines the diverse mechanisms through which Panax notoginseng addresses cardiovascular diseases, including anti-inflammatory, antiplatelet aggregation, anticoagulation, anti-oxidative stress, regulation of angiogenesis, antiatherosclerosis, improvement of microcirculatory disorders and protection against myocardial ischemia-reperfusion injury, highlighting saponins as the principal active components. It also summarizes studies involving Panax notoginseng preparations like Xueshuantong and Xuesaitong in treating coronary heart disease and myocardial infarction, and discusses the safety, limitations, and future research directions of these extracts. In conclusion, the cardiovascular protective mechanism of Panax notoginseng is multi-targeted and multi-pathways, and its clinical application is relatively safe, with rare and mild adverse drug reactions, suggesting a promising therapeutic potential.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0